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Introduction
Statement of the Problem
As of December 2001, the total number of people living with HIV/AIDS (PLHA) is estimated at 40
million. Most of these people live in the developing world (UNAIDS and WHO 2001). While there
are indications that the incidence of HIV infection has been declining in some countries, in many
others incidence rates remain high or are increasing. Consequently, the prevalence of HIV infection
is likely to continue to rise. In the absence of treatment, most people infected with HIV will
eventually develop an HIV-related disease and succumb to the consequences of the infection.
Advances in the development and availability of antiretroviral drugs have led to a paradigm shift in
most of the industrialized world, where highly active antiretroviral therapy (HAART) has resulted
in a significant reduction in the prevalence of AIDS-related morbidity and mortality. AIDS has, in
the eyes of many, become a manageable chronic disease.
In most of the developing world, however, the focus of national programs and international support
continues to be on prevention, care, and support in the absence of antiretroviral treatment. Notable
exceptions are Brazil, Thailand, Senegal, and Botswana, which have made antiretrovirals (ARVs)
available to people with AIDS through public sector efforts. Other exceptions include countries
that have initiated pilot antiretroviral treatment programs, including Côte d’Ivoire, Uganda, Chile,
and Vietnam.
While the moral imperative to provide the best possible treatment for people with AIDS-related
disease is widely recognized, national governments and donors have been reluctant to enter into
this endeavor. They cite numerous concerns, ranging from the cost of ARVs to the capacity of
health care delivery systems in the developing world to the ability of patients to adhere to lifelong
treatment regimens. However, the cost of antiretroviral drugs continues to decrease and ARVs are
now available through private channels in almost all countries in the world. The above-mentioned
concerns remain, however, and both ministries of health and the international donor community
need guidance on how to develop and implement appropriate and effective HIV/AIDS treatment
programs.
A successful treatment program is the result of the synergy between a large number of components.
In an ideal situation, appropriate drugs with few or no side effects are accessible and affordable to
those who need them. Those who need the drugs seek and adhere to treatment freely and without
fear of stigmatization or discrimination, and health care workers monitor treatment and adapt
regimens to suit individual patients. While impressive progress has been made in many of these
areas of HIV/AIDS treatment, numerous challenges and questions remain.
To explore and prioritize operations research questions about access to treatment for HIV/AIDS,
the Horizons Program convened a two-day meeting of international researchers and program
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managers in Washington, D.C., on 12–13 June 2001. The meeting focused specifically on the
following key questions:
•
•
•
•

What are the operational issues encountered in providing HIV/AIDS treatment in different
settings?
What are the most important operational challenges and testable solutions in providing
access to treatment?
How do these challenges and solutions differ by region and subpopulation?
What are some of the important research design and measurement issues that need to be
considered in addressing key issues concerning access to treatment?

This report presents the findings and recommendations discussed at the meeting. The report begins
with a summary review of aspects of antiretroviral programs and then discusses the following
critical elements of treatment programs:
•
•
•
•
•
•
•
•

Health systems and service delivery
Biomedical issues
Behavior of health care workers and clients
Stigma, discrimination, and ethical issues
Community involvement
Cost and cost recovery
Policy
Programmatic issues

The discussions at the two-day meeting covered a wide range of topics at times, but an effort has
been made in this report to concentrate on the important operational issues concerning access to
treatment that need to be addressed through research. It is recognized that treatment for HIV/AIDS
is more than antiretroviral therapy; rather, it includes treatment of opportunistic infections and
palliative and end-of-life care. While the discussion focused on treatment with ARVs, many of the
issues raised and the research questions identified also pertain to treatment of opportunistic
infections and the provision of palliative and end-of-life care.
Finally, the participants at the meeting brought to the table a rich and diverse experience with
HIV/AIDS treatment, care, support, and prevention. Most participants made short presentations
that provided the basis for in-depth discussion. For the purposes of this report it did not seem
desirable to summarize every presentation, but rather to ensure that the substance of the
presentations is accurately reflected.
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Antiretroviral Therapy Programs: Issues and Considerations
The availability of HAART in the industrialized world has greatly reduced AIDS-related mortality,
while the number of PLHA in many countries continues to increase. Thus, in the United States, the
number of PLHA increased from 174,244 in 1993 to 317,368 in 1999, while mortality associated
with AIDS decreased from 45,494 to 16,767 in that same period (CDC 2000). Initially the cost of
ARVs was perceived as an insurmountable obstacle to wide-scale provision of antiretroviral
therapy in the developing world. However, recently these costs have come down to levels that are
affordable to at least some national health systems outside of the industrialized world and to some
individuals in even the poorest countries. For instance, the cost of triple antiretroviral therapy has
decreased from US$800–1,100 per month to US$100–300 per month. This still represents an
enormous cost, however, especially in relatively poor countries with a high prevalence of HIV
infection. Nonetheless, the cost of not providing antiretroviral therapy is also enormous in terms of
morbidity and mortality, declining agricultural and industrial productivity, increased numbers of
orphans, and great economic hardships for affected families.
Comprehensive prevention, care, and support
It is important to realize that antiretroviral therapy is only one component of a comprehensive
HIV/AIDS program that also includes prevention and other care and support activities. Figure 1
provides a schematic overview of a comprehensive HIV/AIDS care program. These components
not only complement but also mutually reinforce each other. Treatment programs are developed
and implemented in the context of existing health care delivery systems. Other components of
HIV/AIDS treatment and care include counseling and testing; the control and management of
sexually transmitted infections (STIs); prophylaxis for certain opportunistic infections (OIs), such
as tuberculosis (TB) and pneumocystis carinii pneumonia (PCP); treatment for OIs; and palliative
care. Many PLHA will not initially qualify for antiretroviral therapy, and not all who receive
antiretroviral therapy benefit equally. Studies in the industrialized world demonstrate highly
variable rates of long-term suppression of viral particles in the peripheral blood, ranging from 32
percent in patients who received antiretrovirals before initiating HAART to 37–82 percent in
patients who had never received antiretroviral treatment (Lucas et al. 1999; Servais et al. 2000;
Yamashita et al. 2001). Lack of long-term benefit is strongly associated with less-than-perfect
adherence, treatment discontinuation, and viral resistance, and possibly with the number of CD4
cells present at treatment initiation. A significant number of people on HAART discontinue
treatment because of serious side effects or psychological and emotional strain.
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Figure 1 Overview of comprehensive HIV/AIDS care program
Socioeconomic Support
Examples:
• Microcredit
• Nutritional support
• Orphan support

Human Rights & Legal
Support
Examples:
• PLHA involvement
• Making a will
• Community sensitization

People and
Families
Affected by
HIV/AIDS
Medical & Nursing Care
Examples:
• OI treatment
• Preventive therapies
• ARVs
• Traditional therapies
• STI treatment

Psychological Support
Examples:
• Voluntary counseling
and testing (VCT)
• Spiritual support
• Follow-up counseling

Source: Eric van Praag, FHI/IMPACT

Although antiretroviral treatment is a rapidly evolving field and experience with such programs is
relatively limited, it is nevertheless clear that as a component of comprehensive care and support
programs ARVs can reduce HIV-related morbidity and mortality and improve the quality of life of
people living with HIV/AIDS. Antiretroviral treatment might also contribute to reduced
transmission of HIV by lowering the viral load and thus reducing the infectiousness of PLHA. The
availability of antiretroviral therapy is likely to provide an incentive to seek voluntary counseling
and testing (VCT) and to learn about one’s serostatus, which in turn might contribute to safer
sexual behavior.
Despite the many problems of antiretroviral treatment programs, they have the potential to
significantly complement and enhance comprehensive HIV care and support programs,
and, possibly, other health care programs. (Eric van Praag, FHI/IMPACT)
Antiretroviral drugs, resistance, and treatment monitoring
Currently, there are three classes of drugs that block replication of HIV in the cell:
•

Nucleoside reverse transcriptase inhibitors (NRTI)–such as zidovudine (AZT), 3TC, ddI,
d4T, ddC, and Combivir (a combined preparation with AZT and 3TC)
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•
•

Non-nucleoside reverse transcriptase inhibitors (NNRTI)–such as nevirapine, delavirdine,
and efavirenz
Protease inhibitors (PI)–such as ritonavir, indinavir, nelfinavir, and saquinavir

Each class of drugs has its own side effects, many of which are potentially very serious. Common
side effects are headache, nausea, vomiting, fatigue, and diarrhea. Some people have problems
eating or sleeping. Some other complications associated with specific classes of drugs include
lipodystrophy (fat redistribution) syndrome, hepatomegaly (liver enlargement), pancreatitis, and
anemia. It is important that both health care workers and people taking antiretroviral therapy are
well aware of these side effects.
A combination of drugs from different classes is required for a sustained reduction of the viral load
in the peripheral blood, because resistance to a single drug usually develops rapidly. At the very
least, treatment regimens should provide for double therapy, but optimal regimens consist of a
combination of three drugs. Current recommendations for triple therapy are two NRTIs and one PI
or two NRTIs and one NNRTI. The only exception to these recommendations is related to the
prevention of mother to child transmission (MTCT), for which treatment of mother and child with
a single drug has been shown to reduce significantly the incidence of HIV infection in the newborn
baby. Treatment regimens are becoming easier to follow by combining different drugs in one pill
or capsule and by developing formulations that require less frequent dosages. Still, some drugs
require refrigeration for storage, and there is no single ideal combination of drugs. For optimal
patient management, careful monitoring of the clinical response to a treatment regimen is needed
so that treatment can be adapted to suit the clinical and immunological response as well as the
needs of the individual patient.
The development of HIV drug–resistant strains is a concern, especially when treatment is
interrupted because of irregular adherence to treatment. Irregular adherence may be due to
interruptions in the supply of drugs, problems with access to services, serious side effects,
intermittent ability to pay for the drugs, or a patient’s increased sense of wellbeing. The fact that
currently available antiretroviral therapy needs to be taken lifelong might also contribute to
adherence problems. Resistant strains not only are a problem in the management of individual
patients, but also could theoretically limit the usefulness of one or more classes of antiretroviral
drugs at the community level.
An additional complication is that many ARVs interact with other drugs that are commonly
prescribed in developing countries, increasing the toxicity of some drugs and reducing the efficacy
of others. This is the case, for instance, with rifampicin, commonly used for the treatment of
tuberculosis, which reduces the efficacy of amprenavir, saquinavir, indinavir, and nelfinavir. It is
important that physicians prescribing and monitoring antiretroviral therapy have a good
understanding of these issues.
Drug therapy for HIV/AIDS is rapidly evolving, and it is likely that treatment recommendations
will continue to change as new drugs and new formulations become available. Treatment programs
should be aware of this and remain flexible so they can be adapted to new developments.
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The impact of HAART is usually measured through assessments of the CD4 count and of the viral
load in the peripheral blood. The CD4 count (the number of T-lymphocytes with a CD4 receptor) is
a measure of the degree to which HIV compromises the immune system, while the viral load
measures the number of circulating viral particles. The CD4 count is also used as a criterion for the
initiation of treatment; persons whose CD4 count falls below a certain threshold are considered
eligible for treatment with ARVs. These tests are expensive, however, costing roughly $100 per
viral load test and $30 per CD4 test, and they demand highly qualified and well-trained laboratory
staff, well-equipped laboratories, and high levels of quality control.
Antiretroviral drugs and the health care system
Implementing an antiretroviral therapy program places an additional strain on a health care system,
in terms of its logistics, the providers, and the laboratory support system. Providers in the public
sector as well as in the private sector, where antiretroviral drugs are generally more widely
available, need to be trained and prepared to provide continuing clinical follow-up. Access to highquality care may be further compromised because of generally high levels of attrition among
physicians and nursing staff resulting from HIV infection (of themselves or their families), low
wages, burnout, and lack of motivation. A consistent supply of antiretroviral drugs must be
available in order to avoid arbitrary treatment interruptions, and there should be sufficient
laboratory capacity to do the initial testing, to assess a person’s HIV status, and to monitor CD4
counts and viral loads. An intensive clinical and laboratory monitoring and information system also
needs to be implemented.
Although drug costs have dropped recently, the cost of antiretroviral drugs still remains
considerable for most individuals and treatment programs. Added to the cost of drugs are the cost
and effort required to strengthen and maintain the capacity of health care systems to deliver
appropriate treatment programs. An HIV/AIDS treatment program could lead to new partnerships
in health care delivery, for example, between the public and private sector, and to the strengthening
of the overall health care system. However, it could also result in situations in which antiretroviral
therapy programs are in competition for resources with other health care programs, and in which an
emphasis on HIV/AIDS treatment leads to a deterioration of other programs, including HIV
prevention efforts.
Behavior, stigma, and discrimination
Persons taking antiretroviral therapy may see less need to adopt or maintain safe behaviors because
they mistakenly believe the treatment is curing them or that the virus is sufficiently suppressed to
render them noninfectious. Similarly, the perception of ARVs as a cure for AIDS may also
undermine behavior change programs and result in fewer people adopting or maintaining safe
behaviors. A recent increase in high-risk behaviors among men who have sex with men in the
United States has been associated with the availability of HAART (Remien 1998; Scheer 2001).
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There are indications that with the widespread availability of HAART and the perception of AIDS
as a manageable, chronic condition, levels of stigma and discrimination in the industrialized world
may have decreased. However, in many parts of the industrialized world and in most of the
developing world, PLHA are still subject to considerable stigmatization and discrimination. While
increased availability of ARVs in the developing world might reduce stigma and discrimination,
communities and PLHA also need to be involved in HIV/AIDS treatment programs to achieve this
goal. It is likely that increased availability of ARVs will result in increased demands for voluntary
counseling and testing and that antiretroviral therapy will result in increased disclosure, either
voluntary or involuntary. Community and PLHA involvement could contribute significantly to
reducing stigmatization while providing a supportive environment for all PLHA. Such a supportive
environment could also play an important role in adherence to treatment recommendations.
However, the current levels of actual or perceived stigma may still prevent people from seeking
VCT and from accessing ARV programs, especially those provided by employers.
Access and equity
Not all people living with HIV need antiretroviral therapy. Whether a decision to treat is based on
the CD4 count, viral loads, evidence of HIV-related disease, or a combination of these factors, it is
likely that initially only a relatively small proportion of all those who are HIV-positive would
qualify for antiretroviral therapy. Moreover, a patient’s readiness to start treatment needs to be
taken into account. This requires a thorough understanding of the need to adhere to a relatively
complex treatment that is to be taken lifelong. The number of patients eligible to start a treatment
regimen is still substantial, with estimates on the order of 10–15 percent of those who are HIVpositive or 3–5 million people worldwide. Over time, as more HIV-positive individuals progress to
HIV-related disease and fewer people die of AIDS, this number could rise considerably. In many
cases the cost of treatment and differences in the capacity of health care systems within countries
will result in unequal access to treatment. Issues of equity will need to be addressed, although it is
not possible to wait until a perfect system is in place before beginning treatment programs. The
effect of insufficient VCT services, inadequate health care–seeking behavior, and the lack of easily
accessible and affordable treatment is shown in Figure 2.
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Figure 2 Estimated proportion of HIV-infected people benefiting from effective use
of ARV drugs: A theoretical model
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Adapted from Eric van Praag, FHI/IMPACT

Equity in access to treatment is especially important if the overriding goal of an HIV/AIDS
treatment program is to achieve a therapeutic effect for all infected persons. Nonetheless, an
argument can be made for the public health benefits of antiretroviral therapy directed at selected
groups of people such as health care providers, teachers, uniformed services, truck drivers, and sex
workers. Another group that could be considered are women who are found to be HIV-positive in
MTCT programs and who play a crucial role as caretakers in the family. Such benefits include not
only a reduction in morbidity and mortality associated with HIV/AIDS at the individual level, but
also a potential reduction in transmission of HIV infection by HIV-positive individuals on
antiretroviral therapy, as reductions in viral load are associated with reduced risk of transmission
(Gray 2001). In the case of mothers, the benefits would include improved survival and
development opportunities for her children and a reduction in the number of orphans. Pursuing the
public health prevention benefits associated with antiretroviral therapy suggests that programs
might focus initially on high-risk individuals or those with multiple partners and that these
programs might start treatment early. Whether the focus of a treatment program is on all infected
individuals or selected high-risk groups, an important question for program managers and
policymakers is one of coverage. Critical decisions have to be made about which segments and
what proportion of the population are to be covered by the treatment program.
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Critical Aspects of Treatment Programs
Health Systems and Service Delivery
Human and institutional capacity
Health care systems and their resource base differ from country to country and even within
countries. The not-for-profit and private sectors play an important role in providing curative care
for many people in the world. In fact, in most countries ARVs were available through the private
sector before public sector programs were developed. Thus, a first step in the development of an
HIV/AIDS treatment program is a situation analysis of the available services, capabilities, and
capacity of the existing system. Particular attention should be paid to the training needs of health
care personnel in the public and private sector, to the quality and location of laboratory services,
and to the existing infrastructure for drug procurement and distribution. As was pointed out earlier,
the care and treatment needs of PLHA are not met by ARVs alone. Services for VCT need to be
available; tuberculosis and other OIs need to be diagnosed and treated; prophylaxis for some OIs
can be provided; and palliative and end-of-life care is required for many infected persons. The
majority of people who are HIV-positive will in fact be asymptomatic; therefore, once they know
their HIV status, they will initially need psychosocial support the most.
A crucial element of a health care system is its staff. The initial situation analysis should pay
attention not only to their levels of knowledge, but also to their motivation and commitment and to
their attitudes toward people living with HIV/AIDS. Frequently, health care workers in the
developing world are overworked and underpaid. They lack supplies, support, and supervision;
they suffer from low morale and poor motivation; and they might fear occupational exposure to
HIV infection. Care for PLHA is often seen as a waste of resources, because those patients are
expected to die anyway. In addition, in many places stigma and discrimination lead to a rejection of
HIV-positive individuals. Therefore, approaches to improve the capacity of health care systems to
provide treatment, care, and support should focus not only on building skills and increasing
knowledge, but also on improving the motivation and morale of staff and on strengthening health
care systems.
Health care systems in many countries suffer from a general lack of resources that leads to
situations in which even essential drugs are often not available, supplies and equipment such as
protective gloves are lacking, and even the presence of running water and electricity cannot be
taken for granted. In turn, such health systems often function against a larger background of
developmental and economic problems, characterized by corruption, internal displacement, civil
strife, poor sanitation and water supply, unemployment, and internal and external migration. Or, as
one participant put it: “We need better African economies.”
The experience with large-scale antiretroviral therapy programs in Brazil and Thailand underscores
the importance of capacity building within the health care delivery system. In Thailand, for
instance, initially only a relatively small proportion of eligible persons received treatment, resulting
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in only a small reduction in the national burden of HIV-related disease. Moreover, health care
workers were not able to follow up on 70 percent of the patients because of a lack of infrastructure.
Constraints to increasing coverage of the treatment program were identified as a lack of counseling
capability, lack of health care personnel trained in ARV therapy, and a lack of clinical facilities
with the capacity to monitor persons on treatment. To increase coverage of the program, qualified
personnel are training staff in 60 hospitals.

Making ARVs Accessible
In Brazil, a network of facilities accredited for the provision of ARVs has been developed,
where staff have been trained in both patient care and the interactions between ARVs and
other drugs. Currently, 362 hospitals have been accredited to provide HIV/AIDS care. In
addition to these facilities, outpatient and ambulatory care is provided through specialized care
services at 148 facilities, 69 day hospitals, and 52 therapeutic home care initiatives.
Laboratory capacity to conduct CD4 testing (70 laboratories) and viral load assessments (63
laboratories) has also been developed.
The UNAIDS-supported pilot program for the provision of ARVs in four countries (Vietnam,
Uganda, Cote d’Ivoire, and Chile) started with developing human resources to support the
programs, while making optimal use of existing services.
In Uganda three centers for ARV treatment were operational in 1999; this is now being
expanded to more than ten centers, which are expected to be qualified in 2001. In addition,
planning is under way for three regional centers to provide services at the district level.

While there is no doubt that training both public and private sector health care providers in
HIV/AIDS care is needed, there is also an urgent need to evaluate the effect of quality-of-care
training on health service use and the impact of such training on health. Guidance and training
materials have been produced by WHO, UNAIDS, and other organizations (see References for a
selection of materials for further reading).
Interaction between HIV/AIDS care and other programs
Countries in the developing world are typically faced with a range of health problems. While
HIV/AIDS may have become one of the leading causes of morbidity and mortality in many
countries, other infectious and noninfectious diseases remain important. There is a risk that the
increased focus on antiretroviral therapy programs will be at the expense of established health care
programs, many of which are already in need of additional funding and strengthening.
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Within HIV/AIDS programs the allocation of resources needs to be carefully assessed. As was
pointed out earlier, the provision of relatively expensive antiretroviral therapy is only one
component of a comprehensive care program. It is by no means clear what the relative gains in
quality-of-life and survival benefits are for those in ARV programs versus the benefits derived
from less expensive prophylaxis and management programs for opportunistic infections. The
UNAIDS pilot program for the provision of ARV was not able to document survival benefits or to
demonstrate a reduction in the incidence of OIs and TB, possibly because many patients sought
treatment very late in the course of their illness. Data from Brazil suggest that at least in the short
term there is a reduction in mortality associated with the provision of HAART (Eyer-Silva 1998)
and a reduction in the incidence of opportunistic infections. In Brazil, AIDS-related mortality
dropped by 50 percent from 12.2/100,000 population in 1995 to 6.3/100,000 in 1999, while the
incidence of various OIs decreased by 60-80 percent (Ministry of Health of Brazil 2001). There is
an urgent need in the developing world to evaluate both ARV treatment programs and programs for
the management of OIs for their impact on morbidity and mortality.
An excessive focus on antiretroviral therapy is an impediment to establishing a
comprehensive care agenda, and an obstacle to decentralization. (Jos Perriens, UNAIDS)
While some people argue that expensive ARV programs will weaken other health programs, it has
been postulated that just the opposite could happen. The current attention to improving the systems
for providing VCT and care for people with HIV/AIDS might also have a “ripple effect” of
strengthening other health care systems. For instance, in Brazil, programs to increase access to
antiretroviral therapy have increased local capacities for research, training, distribution of essential
drugs, and management of complex information systems, and have led to better-integrated alliances
between government, NGOs, and the community. Health planners need to balance an approach that
calls for designing and implementing new systems to provide HIV/AIDS services and an approach
that aims at improving and building on existing programs for providing these services. Operations
research needs to determine the effect of each of these approaches.
Within HIV/AIDS programs there is a similar need to balance care and prevention. The cost and
effort required to deliver high-quality care and treatment may divert resources from ongoing
prevention programs. It is therefore important to assess how strengthened HIV treatment programs
will affect prevention programs.
Finally, many PLHA will be need palliative and end-of-life care. This will be the case for those
who do not receive antiretroviral treatment, those who stop treatment, and those in whom the virus
has become resistant to the available antiretroviral drugs. Little is known about how to best provide
palliative and end-of-life care and the needs of professional and lay caregivers to provide such care.
Service delivery models
A range of different service delivery models is being proposed, and operations research is needed
to help evaluate the various approaches. The shortcomings of many health delivery systems in the
developing world and the urgent need to address the care and support needs of ever-increasing
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numbers of people who have HIV-related diseases may seem to suggest a vertical approach to HIV
treatment programs. It might be easier to ensure drug logistics, prevent pilferage and misuse of
antiretrovirals, and train and supervise dedicated staff in a vertical program. However, the large
number of people who need care and support, the many facets of a comprehensive HIV care
program, the complexities of a treatment delivery and monitoring system, and the imperative to
implement programs that are sustainable suggest that an integrated approach might be more
successful. An integrated approach will in many cases require a concerted effort to strengthen the
health care system beyond the narrowly defined needs of an antiretroviral treatment program.
An important component of a treatment program is laboratory support. Current approaches to
identifying individuals eligible for treatment with ARVs and to monitoring patients on treatment
rely on CD4 and viral load tests. These tests are expensive, at US$30 and $100 per test,
respectively, and require a sophisticated laboratory infrastructure with good quality control. An
urgent need exists to evaluate alternative methods of patient follow-up that rely on fewer or less
frequent laboratory tests and that might be more appropriate for many developing country settings.
The tuberculosis model
Irregular adherence to treatment will almost inevitably lead to the development of viral resistance.
Antiretroviral treatment is thus very much like treatment for tuberculosis. It has therefore been
suggested that ARVs might be delivered via the vertically implemented tuberculosis model, in
which a health care worker directly observes treatment-taking behavior. This approach needs to be
evaluated in how well it can be applied to HIV treatment programs, as there are a number of
significant differences between HIV treatment and TB treatment. For instance, TB treatment
consists of a fixed combination of drugs, and this combination does not need to be adapted to suit
individual patients. Even more important, TB treatment is taken for a limited period of time,
typically for six months in short-course treatment regimens, while antiretroviral treatment is
lifelong. The latter requires a different relationship between health care providers and clients and
over a much longer period of time. There is certainly merit in some form of observed treatment,
but, given that a very large number of people might eventually be on antiretroviral treatment, there
is also a need to explore involving non–health provider observers, such as family members,
treatment buddies,1 or members of the community, as long as they are chosen or identified with the
explicit consent of clients and not by the health system alone.
Public and private models
Many people living with HIV/AIDS will seek care through the private sector, which in many
developing countries is still the only source of antiretroviral therapy. This suggests the need for
public-private partnerships to build on the strengths of each sector and also to address a number of
1

“Buddy” is a term used to describe a family member, friend, or acquaintance who provides one-on-one
support to a person living with HIV/AIDS.
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concerns. One concern is the quality and consistency of care. Additional training of both public and
private physicians in antiretroviral treatment is needed. Another issue is the very real possibility
that clients on treatment will move from provider to provider according to their ability to pay and
the availability of drugs. This carries the risk of changes in treatment regimen and thus of drug
resistance. In addition, patients with limited financial resources may put pressure on providers to
avoid expensive antiretroviral combinations and expensive laboratory tests. This underscores the
importance of collaboration, and, when indicated, referral, between the public and private sector.
Within the public sector, questions arise about which type of health care worker should provide
antiretroviral therapy, and at what level of the health care system this treatment should be provided.
In other words, what is the lowest level at which treatment decisions can be made while still
maintaining an acceptable level of quality of care, and what is the lowest level for monitoring
treatment?
Antiretroviral treatment programs: Access and equity
The health care delivery system, whether private or public, plays a key role in providing
antiretroviral therapy. Many research questions about these systems were identified at the meeting,
some of which are more biomedical but many of which are amenable to an operations research
approach. While there is agreement that antiretroviral treatment is only one component of a
comprehensive care program, it is not clear what the key components of such a program are and
what the appropriate mix of treatment and care is at different levels of the system.
Managers of antiretroviral treatment programs need to make decisions about the number and types
of antiretroviral drugs that need to be available, and they need to establish guidelines and treatment
protocols. A sustainable and continuous supply of drugs needs to be guaranteed, but the program
needs to be flexible enough to adapt to new developments.
Decisions also need to be made about the eligibility of individuals to receive treatment—in other
words, what are the criteria a person needs to meet to begin receiving antiretroviral therapy? This
in turn raises the issue of equity in access to treatment, or who will have access to ARVs. One of
the criteria currently used in Uganda, for instance, is the client’s ability to cover the cost of the
drugs. While such an approach contributes to the sustainability of the program, it also raises a
number of concerns. Current treatment costs, even if subsidized, make treatment unaffordable to
many, and may result in the serious risk of treatment interruptions for those who can afford
treatment only intermittently. This, obviously, is not a problem in countries where ARVs are made
available free of charge through the public sector, although these subsidies come at considerable
cost to the government. In Thailand, for instance, 70 percent of the government AIDS budget is
allocated to treatment and care, which includes laboratory support, screening, capacity building,
treatment for OIs, and ARVs. Even in countries where treatment is free of charge, clients
sometimes incur considerable direct and indirect costs, such as transportation and loss of income.
Antiretroviral treatment programs could benefit greatly from involving people living with
HIV/AIDS, to assist in planning for service delivery as caregivers and as educators to reduce
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stigma and discrimination, and to educate the public, clients, and health care workers. Different
approaches to involving PLHA need to be explored and evaluated.

Biomedical Issues
Antiretroviral therapy is a rapidly evolving field, with new drugs and new drug combinations
becoming available continually. While storage requirements have become simpler and treatment
regimens have become less complex, further simplification of treatment regimens might make
large-scale treatment programs easier to implement and more feasible. Further research and
development are also needed to reduce the side effects and toxicity of ARVs. The effects of
structured treatment interruptions on quality of life and on viral suppression are currently being
explored. Structured treatment interruption might provide a cost-effective approach to maximizing
availability of and access to antiretroviral treatment, while minimizing the impact of drug toxicity
and side effects on individual patients. Cost savings associated with treatment interruptions might,
however, be offset by the need for frequent viral load and CD4 counts to monitor patients.
Resistance to antiretroviral drugs develops rapidly in patients on mono-therapy and more slowly in
patients on dual or triple therapy. However, even patients on triple therapy develop resistance, and
mechanisms need to be put in place to monitor the response of patients to treatment. Viral strains
that are resistant to one or more classes of antiretroviral drugs are especially likely to develop
rapidly when adherence to treatment regimens is poor. The presence of resistant strains in a country
requires that a larger selection of ARVs be provided, which in turn complicates individual patient
management, increases the risk of adverse drug interactions, and increases the demands on the
health care and drug logistics systems.

Behavioral Issues
The health care needs of people living with HIV/AIDS can be seen as a continuum, both in terms
of the ever-changing needs as people infected with HIV progress toward AIDS and, in many cases,
death, and in terms of the relationships between individuals and their direct environment and the
wider community. Figure 3 illustrates the continuum of care as it relates to HIV infection. A
comprehensive HIV/AIDS care program must address the full continuum, which usually requires
involving a large number of different partners, including PLHA, their families, and health care
providers.
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Figure 3 HIV/AIDS and the care and support continuum

Behaviors

Care and
support
services

Infection

Living with
HIV

Health
seekingbehavior

Living
“positively,”
disclosure

Health
seekingbehavior,
adherence

Will making,
successionplanning

VCT

Psychosocial
support,
prevention of
HIV
transmission

Access to
ARVs,
treatment for
OIs, homebased care

Home-based
care,
psychosocial
support,
palliative care

Living with
HIV-related
illness/AIDS

End-of-life
concerns

Note: Many behaviors and care and support activities are relevant across the whole continuum.

Health-seeking behavior is a complex issue that is influenced not only by the availability of
services or treatment, but also by the perceived benefit of such services and by their accessibility
and affordability. For example, experience in the United States has shown that migrant workers are
often not aware of what services are available to them, have little confidence in public sector
services, or may lack the means to access such services. Women in many developing countries
have very limited access to available services. Service providers need to understand their clients
and their needs and tailor services accordingly. Community-based organizations can play an
important role in providing information and education and in working with service providers to
increase the coverage and use of services. Community education efforts might help create a more
supportive and conducive environment for care and treatment programs, and might lead to more
realistic expectations for such programs. Involving people living with HIV/AIDS in care programs
can also greatly contribute to a better understanding of the needs of PLHA and might reduce stigma
and discrimination within the community, thus reducing an important barrier to care.
A first step in the continuum of care for HIV/AIDS is voluntary counseling and testing, as depicted
in Figure 4. VCT services in many countries in the developing world are currently not able to meet
the demand for such services. Yet as ARVs become available, it is likely that demand for VCT will
increase rapidly. Alternative ways to offer VCT, including making them available outside the
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traditional health care system, should be considered and evaluated. Moreover, the impact of testing
and counseling on the psychosocial health of individuals needs to be explored.
Figure 4 VCT: An important entry point for HIV prevention and care
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The care continuum for HIV/AIDS, as shown in Figure 4, is characterized by frequent interactions
between clients and health care providers, and provider behavior and attitudes are important in
determining the acceptability, use, and success of treatment programs. It is important that program
managers in treatment programs develop a good understanding of staff attitudes and behaviors and
of staff motivation and fears. Staff training and support activities need to address a lack of
understanding of the nature of HIV infection and AIDS, fear of contagion, and judgmental and
pejorative staff attitudes. In addition, given the strong emotional issues around HIV/AIDS,
psychosocial support services for health care staff should be made available. Finally, the care
continuum requires good collaboration and referrals between all of the various service providers,
institutions, and programs involved.
People with HIV who seek care early on are unlikely to be eligible for or to need antiretroviral
therapy. They will often, however, require psychosocial care and support to deal with the
knowledge of being infected with HIV and with issues of disclosure, further prevention of
infection, and possible stigma and discrimination. Professional sources of psychosocial support are
likely to be limited and it is suggested that lay sources be explored. An important source of
psychosocial support could be the family and the community, provided that issues of disclosure,
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associated stigma and discrimination, and possible disclosure-related violence are addressed.
Psychosocial support is also an important component of home-based, palliative, and end-of-life
care.
The provision of antiretroviral therapy raises a large number of behavioral issues, many of which
are poorly understood and therefore in need of further research. Clients and communities need to
understand that not everyone who is HIV-positive needs immediate treatment; but that once
treatment is initiated it needs to be continued lifelong. Moreover, arbitrary treatment interruptions
may lead to viral resistance, which may jeopardize future treatment. However, structured treatment
interruptions may contribute to long-term adherence, by temporarily removing the pressure of daily
treatment adherence and by alleviating side effects of ARVs. Thus, adherence to treatment
regimens is a major concern. In Brazil, for instance, intensive public and private sector efforts are
made to promote adherence, but these have not been evaluated well enough. It was noted, however,
that adherence tends to be poorer for people of lower socioeconomic status.
Little is known about what determines good adherence, and this should be an urgent focus of
operations research. Lessons could be learned from directly observed treatment (DOT) programs
for tuberculosis, for which treatment defaulting has been linked to an inadequate understanding by
patients of the disease and the treatment program. The effect on treatment adherence of an
approach that combines early testing and the preparation by the health care provider and the client
of a long-term management plan should be explored. Different approaches to ensuring treatment
adherence should be evaluated, such as ways to help clients disclose and involve others in
adherence, the use of treatment buddies, group approaches to treatment, use of treatment managers
(professional or lay), and home and community support.
An area of special concern is the effect of antiretroviral therapy on protective and preventive
behaviors. It has been speculated that the availability of antiretroviral therapy has changed the
perception of HIV/AIDS from a universally fatal condition to a manageable chronic disease.
Consequently, there might be less incentive to adopt and maintain preventive behaviors (Scheer et
al. 2001; Stolte 2001 et al.). However, this association has been made on the basis of crosssectional studies that may not necessarily capture other factors that contribute to changes in risk
behavior. Longitudinal studies are needed to further explore this issue. It was pointed out by
meeting participants that there might be substantial misunderstanding and incorrect interpretation
of statements about the outcome of antiretroviral treatment. For instance, statements about an
undetectable or low viral load as a consequence of antiretroviral treatment should not be
interpreted as meaning that people on treatment are cured or that they cannot infect others.
Clarifying these kinds of issues requires a clear communication strategy, not only for patients but
also for communities at large.

Stigma, Discrimination, and Ethical Issues
Successful HIV/AIDS programs, whether they focus on prevention or on care and support, demand
careful attention to human rights issues, especially the rights of people living with HIV/AIDS.
Some of these rights include the right to know one’s HIV status, the right to disclose one’s HIV
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status, the right to confidentiality, the right to refuse participation in clinical trials, and the right to
be treated with dignity and respect. These rights are severely compromised by stigma and
discrimination, which still prevail in many parts of the world. For example, fear of stigma and
discrimination will likely limit the number of people seeking VCT and thus treatment in some
situations, while in others actual discrimination by health care providers reduces access to care and
treatment for people living with HIV/AIDS. The impact of involving PLHA in prevention, care,
and treatment programs on human rights issues needs to be further evaluated.
The availability of ARVs may lead to a decrease in stigma and discrimination, as seems to have
happened in parts of the industrialized world, or it may increase stigma and discrimination.
Community involvement, the involvement of PLHA, and a good general understanding by the
population of the potential benefits and the limitations of HIV/AIDS treatment and care might help
reduce stigma and discrimination. On the other hand, limited availability of treatment in
combination with increased disclosure by those seeking treatment or those on treatment might have
the opposite effect.
Instruments have been developed in some places to measure stigma and discrimination, but more
work needs to be done in this area. Using such indicators would allow for an assessment of the
degree to which human rights are respected in service delivery programs and the effect of such
programs on stigma and discrimination.
Countries must ensure that the conditions necessary for the health of individuals and populations
are met. This responsibility raises questions about equity of access to information, means of
prevention, and treatment. At the same time, resources are limited and public health programs are
often forced to ration and prioritize. While universal access to cost-effective drugs for palliative
care, treatment of opportunistic infections, antiretroviral drugs, and behavior change programs is
the ultimate goal, choices have to be made in the meantime that will almost always lead to
inequities in access. Broad-based advocacy for access to treatment, as happened in Brazil and
Thailand, may increase the demand for and the availability of treatment. In other parts of the world,
community mobilization could also prove to be an important step in increasing access to treatment.
It is important that programs define indicators to identify inequities in access to treatment and to
monitor progress toward greater equity. In the meantime, many questions remain about who has or
will have access to treatment and what criteria should be applied to determine eligibility for ARV
treatment. The application of clinical criteria seems fairly uncontroversial, but criteria regarding
ability to pay, membership within a particular community, expectations concerning adherence, or
geographic location are all likely to result in considerable inequity. While diagnostic studies might
document current practices, operations research is urgently needed to support program managers in
making sound, ethical decisions to determine access and selection criteria. Such research should
also focus on a possible role of communities in deciding on and developing eligibility criteria.
Choices concerning the range of ARVs available in a country also raise ethical questions. What are
the implications of introducing a cheaper, but not necessarily optimal, combination of ARVs? For
instance, highly active triple antiretroviral therapy might offer the highest success rates, but the
cost might also preclude wider coverage of the program. Dual therapy with somewhat cheaper
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drugs might be less effective, but could be offered to a much larger proportion of the eligible
population.
A number of ethical issues also arise concerning research, especially concerning clinical trials.
Local ethical standards should be applied, but one unanswered question relates to the obligation of
researchers after the end of a clinical intervention trial. Should the researchers provide lifelong
antiretroviral treatment to study participants? Is there an obligation to extend such treatment to
others such as partners of people enrolled in the clinical trial or even to all eligible persons in the
community?

Community Involvement
The community is an essential element in the life of individuals, providing context, cultural
identity, and a network for care and support. Yet, with HIV/AIDS, lack of understanding, fear, and
stigma and discrimination often mean that such support is lacking and that people living with
HIV/AIDS are isolated. Community involvement is thus an important facet of HIV/AIDS
programs, to reduce stigma and discrimination and to increase the potential for community care and
support. In addition, involving NGOs and community-based organizations (CBOs) in program
planning and implementation will probably help in formulating more appropriate and more
sustainable programs.
In terms of a community’s understanding of HIV/AIDS, a first step is to provide accurate
information. Beliefs that either antiretroviral drugs or traditional treatments are curative need to be
dispelled, while helping people understand that a range of care and treatment options other than
only antiretroviral drugs is available. Training needs to be provided to NGOs to develop their
capacity to deal with the various aspects of treatment programs, and to develop partnerships
between organizations or institutions providing care, including antiretroviral treatment, and local
NGOs and CBOs. Issues that can be addressed through such partnerships include disclosure, stigma
and discrimination, community care and support, and resource mobilization. The community is also
an essential partner in terms of articulating its needs with regard to a range of other health issues.
Communities without established NGOs or CBOs offer a special challenge for community
involvement.
NGOs can play an important role in providing and supporting home-based and palliative care.
Much can be done in palliative care that would improve the quality of life at relatively little cost.
NGOs can also play an important role in helping individuals make decisions about allocating
resources for HIV/AIDS and in planning for the future, including ways to care for orphans.
Many NGOs and CBOs working in HIV/AIDS will attract people living with HIV/AIDS as
volunteers or collaborators, although fear of stigma may prevent full disclosure. PLHA have,
however, a unique role to play in promoting appropriate care and support, in providing insights into
adherence issues, and in identifying their education and information needs.
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It is essential that community people and community agencies are an integral part
because they are not going to leave and they have the passion. (R. Cameron Wolf, HRSA)
Community outreach is an important component of HIV care programs, to improve community
understanding, increase health care–seeking behavior, reduce stigma and discrimination, and
provide community- and home-based care and support. However, community outreach programs
have not been evaluated, and questions remain about the potential and outcomes of home-based
care programs, especially concerning training and psychosocial support needs of family health
caregivers. One particular group of individuals that could possibly be more involved in care and
support are traditional healers. Their involvement fits well with an identified need to tap into the
spiritual and broad cultural beliefs of the community.

Cost and Cost Recovery
Many see the cost of antiretroviral drugs as the limiting factor in making therapy widely available.
For instance, cost was identified as a major impediment in scaling up in the UNAIDS pilot
programs in Uganda, Chile, Côte d’Ivoire, and Vietnam. Most patients did not have enough
resources to pay for the drugs, and this sometimes led to treatment interruptions. Moreover, as new
drugs become available and as countries move from single or dual therapy to triple therapy, the
cost is likely to increase even more.
While a discussion of the cost of treatment is thus inextricably linked to the broader issue of access
to treatment, many unanswered questions need to be investigated. An important question
concerning any intervention is whether it is affordable, replicable in a larger geographic area, cost
effective, and sustainable over time. In other words, is the intervention worth the investment of
scarce resources?
In terms of affordability and sustainability, one should balance the cost of treatment against the
individual and societal savings that might accrue from treatment. It is also necessary to consider
who pays for treatment (government, individuals, insurance agencies, NGOs) against who benefits
and how many people benefit. For instance, who is willing and able to contribute to treatment
costs? While a patient on treatment might use household savings to pay for treatment, being on
treatment might also guarantee continued income to the household.
In terms of providers, there is not enough experience with providing antiretroviral therapy to know
what the direct and indirect costs are for service providers, and what the health care system will
save in terms of future care costs. Little is also known about the short-term and long-term costs and
savings to society. The larger the savings to society (the external benefits of treatment of
individuals that accrue to the society), the stronger the argument for subsidizing antiretroviral
treatment. Related to this issue is the question of the potential for community mobilization of
resources. Different approaches to funding and resource mobilization, including insurance plans
and risk pooling, need to be explored and evaluated.
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As was pointed out earlier, there is a moral imperative to provide the best possible treatment to
people who are ill with HIV/AIDS. The scarcity of resources, however, means that treatment
programs will be in competition with other programs and that even within treatment programs,
choices will have to be made. Some of these choices are discussed under the Health System and
Service Delivery section. Cost-effectiveness analyses could assist in making such choices, but
many questions still remain about measuring cost-effectiveness of HIV/AIDS treatment programs.
One such question is, what is the objective of the program? For instance, measuring outcomes in
terms of reduced mortality or of disability-adjusted life years2 gained focuses on direct individual
benefits but does not capture external outcomes. Measuring effectiveness requires a clear,
unambiguous definition of outcomes at multiple levels: individual, family, community, and society.
Given the resource constraints under which many countries are operating, a case could also be
made to evaluate and compare the cost-effectiveness and cost benefits of antiretroviral treatment
programs against the cost-effectiveness and cost benefits of other public health programs, such as
malaria control, diarrhea control, and family planning.

Policy
The success of the antiretroviral therapy program in Brazil in providing treatment to substantial
numbers of PLHA has been attributed to high levels of political support and the adoption of
countrywide policies. A federal law passed in 1996 guarantees that ARVs will be provided for any
person who needs them. An important factor in generating this political commitment has been the
presence and activities of vocal and well-organized NGOs and political activists. Similarly, the
success of the Thailand antiretroviral treatment program can be ascribed to the political will and the
commitment to allocate a substantial proportion of the available resources to care and treatment of
PLHA. In all fairness, it should be noted that in both Brazil and Thailand the resource base is much
larger and the prevalence of HIV/AIDS is much lower than in many other developing countries,
especially those in Sub-Saharan Africa. Even so, in Brazil a policy has been adopted to allocate
considerable resources to the manufacture and importation of generic versions of patent-protected
drugs to meet the country’s needs.
But even in resource-constrained settings, governments can do much to create an environment that
is conducive to effective prevention as well as appropriate care and support. Legislation against
discrimination against those with HIV/AIDS and active promotion of their human rights will
facilitate disclosure and help to strengthen services that respect and provide care for PLHA.
Legislation and policies are needed to ensure the availability of condoms and other barrier
methods, youth-friendly services, interventions to prevent transmission through drug injections to
treat opportunistic infections, and, eventually, antiretroviral drugs. Research is needed to better
understand and evaluate approaches to generating appropriate policy support for prevention, care,
and support.

2

Disability-adjusted life years (DALYs) provide a measure of the burden of disease, taking into account both
death and disability (loss of quality of life) caused by a disease (World Development Report 1993).
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Programmatic Implications
To implement a successful, sustainable HIV/AIDS care and support program, a number of
programmatic decisions need to be made. Further operations research is needed to inform such
decisions, but some programs will certainly be implemented in the absence of research results.
Among the many programmatic issues that have been identified as important are discussed below.
HIV/AIDS programs need to balance prevention and care, and care programs need to take into
account the needs of people living with HIV/AIDS along a continuum. This continuum ranges from
testing, counseling, and psychosocial support to treatment of opportunistic infections, prevention of
mother-to-child transmission, treatment with ARVs, and, finally, palliative and end-of-life care.
The resources available and the epidemiological situation will influence the appropriate mix of
activities along this continuum, but even a modest treatment program will require an expansion of
VCT programs for HIV-positive individuals so that they are identified.
For an antiretroviral therapy program to be successful, important decisions have to be made
concerning the types and combinations of drugs that are made available, the criteria used to select
PLHA to receive antiretroviral treatment, and the treatment delivery program that needs to be
developed and implemented. Care should be taken to ensure equitable access to treatment, although
it is unlikely that true equity will be achieved early on in treatment programs. Innovative
approaches to promote treatment adherence need to be tested, such as the joint (client and provider)
development of a treatment plan, the use of a treatment manager (health professional or lay
person), or the use of a treatment buddy system. Communities and PLHA should be actively
involved in the planning as well as implementation stages of the program, and the effect of such
involvement should be evaluated.
In addition, program managers need to develop and implement training programs for health care
providers in the public and private sector, paying attention not only to clinical skills and
knowledge, but also to attitudes and motivation.
One of the biggest challenges, however, of an HIV/AIDS treatment program is to scale up in an
equitable and sustainable manner. Lessons can be learned from experiences with the scaling up of
programs to prevent MTCT.
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Conclusion
Providing antiretroviral therapy as a component of comprehensive HIV/AIDS care is rapidly
becoming a reality in some countries and is becoming a distinct possibility in many other
developing countries. Many questions remain, however, about the most effective, equitable, costeffective, and, above all, balanced implementation of such programs. Biomedical research will
yield new and better drugs that are less toxic and easier to take. Clinical research will continue to
improve and adapt drug combinations, taking into account viral resistance and side effects.
However, considerable operations research is urgently needed to identify, analyze, and disseminate
best experiences with treatment programs in different resource and epidemiological situations. A
list of high-priority operations research questions is provided below, as formulated by the
international experts participating in the Horizons Access to Treatment meeting. Although many of
these research questions can be addressed in the context of ongoing or newly established treatment
programs, there are advantages to identifying specific learning sites for ARV programs in which
different models of VCT and treatment provision can be tested and evaluated.

High-priority Operations Research Questions
Health systems
1. What is the most appropriate mix of care interventions in settings with considerable
resource constraints? What is the most effective way to identify the different needs of
different groups (for example, by age, sex, or geographical location) for care?
2. What are the factors and characteristics that make for successful service delivery
programs? What are the benefits of models with centralized versus decentralized
providers?
3. What is needed to improve the motivation and confidence of health care workers?
Specifically, what is needed in terms of training, salaries, support, and backstopping? What
training is needed for health care workers in the private sector?
4. Where and at what level of the health care system can antiretroviral therapy be provided?
What are the minimum requirements for infrastructure, laboratory support, combination of
drugs, staff, and community involvement that are needed to maintain a basic standard of
quality of care?
5. What are the quality of care and the use of different service delivery models? How can
quality of service be ensured?
6. How can the potential of private providers best be maximized? What are models for
successful public-private sector partnerships?
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Behavioral questions including adherence
1. Which factors contribute to adherence to treatment, for both OIs and ARV therapy?
2. What is the impact of comprehensive care and prevention programs on adherence?
3. How does the use of non-medical providers affect maintenance of treatment regimens?
What is the effect on adherence of using a buddy system compared to treatment managers
or to involvement of family and/or community?
4. Can ARVs be introduced without reducing protective behaviors? Will the introduction of
ARVs increase high-risk behaviors?
Equity and accessibility
1. How equitable is the provision of treatment (for both OIs and ARVs) and what are the
criteria being used to select recipients of ART? How are these criteria developed, applied,
and enforced?
2. What are the specific needs of different groups in a society for care and treatment, and who
can best meet these needs?
3. From an epidemiological and a public health benefits standpoint, are there some high-risk
groups that should receive priority in receiving treatment?
Community involvement
1. What processes or approaches help ensure the meaningful involvement of communities in
designing and implementing HIV/AIDS care and treatment programs? What is the effect
of involving communities in designing and implementing treatment and care programs?
What is the role of communities in care provision?
2. What are the community’s preferences for accessing treatment, in terms of sources of care
and types of care?
3. What is the effect of involving PLHA on the coverage, use, and success of treatment
programs?
4. What is the effect of comprehensive programs that treat families rather than individuals?
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Cost
1. What are the most feasible and effective models for resource mobilization, including risk
pooling, insurance, and community resource mobilization?
2. What is the range of costs and cost-effectiveness for different care options, including
antiretroviral therapy and treatment for opportunistic infections? What is the range of costs
and cost-effectiveness for different treatment options?
3. How much will care and support for people living with HIV/AIDS cost? What is the
benchmark for cost-effectiveness? How big are the externalities3 associated with care and
support, and how can these be maximized?
4. What proportion of therapy can user fees cover? What is the willingness and ability of
clients to pay for different treatment options?
5. What is the implication of user fees on the financial wellbeing of families?
Stigma, discrimination, and ethical issues
1. Which training or other approaches are likely to reduce reducing stigma and discrimination
among health care providers?
2. What effect will scaling up VCT and care and support programs have on stigma and
discrimination? What is the effect of the availability of treatment on stigma and
discrimination?
3. What type of care, support, and treatment interventions will reduce stigma and
discrimination in the community and in the health care sector?
4. What is the scope for providing antiretroviral therapy for prevention purposes? What are
the ethical and patient management implications of such therapy?

3

Externalities are the benefits that go beyond the individual benefits, such as, for instance, the benefit to
society of a person returning to an economically productive life.
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List of Participants at Horizons Access to Treatment Meeting
12 and13 June 2001
Washington, D.C.
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Appendix C
Access to Treatment for HIV/AIDS:
Directions for Operations Research Consultative Meeting
12 and 13 June 2001
Washington Plaza Hotel, Jefferson Room
Massachusetts Ave. and 14th Street N.W.
Washington, D.C.

Objectives
Assist the Horizons Program in refining and prioritizing operations research questions that address
access to treatment for HIV/AIDS, and to identify potential research partners. The meeting will
focus on the following key questions:
1. What are the operational issues encountered in providing HIV/AIDS treatment in different
country settings?
2. What are the most important operational challenges and testable solutions in providing
access to treatment?
3. How do these challenges and solutions differ by region and subpopulation?
4. What are some of the important research design and measurement issues that need to be
considered in addressing key access to treatment issues?

Agenda
Tuesday, June 12
9:00 – 10:00

Introduction of participants and objectives
Andrew Fisher, Horizons

10:00 – 10:40

Overview And Discussion of Access to Treatment Services
Eric van Praag, FHI/IMPACT

10:40 – 11:00

Coffee Break

11:00 – 11:30

USAID's Access to Treatment Priorities and Programs
David Stanton, USAID

11:30 - 12:00

Reaching the Hard to Reach in the United States: Treatment Priorities and
Program Approaches
Barbara Aranda-Naranjo and R. Cameron Wolf, HRSA

12:00 - 12:30

Discussion
Moderator: Simon Baker, Horizons

12:30 - 1:30

Lunch
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Balance of Day

Critical reflection on country experiences with access to treatment
for HIV/AIDS: What does a country need to do to increase access to
treatment? What are the challenges? What are the potential solutions?
What operations research has been done within countries on access
issues? What was learned? What research needs to be done? The format
is 15 minutes for each presentation followed by 5 minutes for clarifying
questions. After all of the country presentations, a general discussion will
follow.

1:30 - 1:50

UNAIDS Four Country Pilot Provision of ARVs
Jos Perriens, UNAIDS

1:50 - 2:10

Thailand
Somsong Rugpao and Anupung Chitwarakorn, Department of
Communicable Disease Control, Ministry of Health, Thailand

2:10 - 2:30

Uganda
Peter Mugyenyi, Joint Clinical Research Centre

2:30 - 3:00

Discussion
Moderator: Ann McCauley, Horizons

3:00 - 3:20

Break

3:20 - 3:40

Brazil
Francisco Inácio Bastos, Oswaldo Cruz Foundation

3:40 - 4:00

South Africa
Mark Lurie, Medical Research Council, South Africa

4:00 - 4:20

India
A.K. Ganesh, YRG Care

4:20 - 5:00

Discussion
Moderator: Naomi Rutenberg, Horizons

5:00 – 6:30

Reception

Wednesday, June 13
9:00 - 9:30

Synopsis of Challenges and Solutions from Previous Day
Johannes van Dam, Horizons

Balance of Day

Discussion of Five Key Topics: For each topic, identify operations research
questions, design and measurement challenges, problem areas, and
potential testable solutions.
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9:30 - 10:20

Service Delivery, Illustrative Questions: What are the supplies,
equipment, and logistics issues that need to be addressed? What are the
provider competence issues? How can we create PLHA-friendly treatment
centers? What are the implications for voluntary testing and counseling of
increased access to treatment? Is there an opportunity to change MTCT
programs, moving from single therapy to triple therapy?
Presenter: Sam Kalibala, Horizons
Moderator: Helena Walkowiak, MSH

10:20 - 10:40

Coffee Break

10:40 - 11:30

Behavioral Issues, Illustrative Questions: How can a high level of
patient adherence to drug regimens be maintained? Is a DOT program
feasible? Are there dangers of an increase in unsafe sex practices as ARV
patients perceive themselves to not be at risk?
Presenter: Julie Pulerwitz, Horizons
Moderator: Mary Bassett, University of Zimbabwe

11:30 - 12:20

Community Involvement, Illustrative Issues: What is the role of
communities and NGOs in access to treatment? How can they foster a
high level of patient adherence and facilitate information dissemination,
particularly among low-literate populations?
Presenter: Eka Esu-Williams, Horizons
Moderator: Stephen Kinoti, SARA Project, AED

12:20- 1:30

Lunch

1:30 – 2:20

Human Rights, Illustrative Questions: What are the human rights,
equity, ethical, and gender issues concerning who will have access to
treatment? Can treatment programs reduce stigma and discrimination?
How can treatment programs accurately track patients without stigmatizing
them?
Presenter: Chris Castle, Horizons
Moderator: Ron MacInnis, USAID

2:20 – 3:00

Cost, Illustrative Questions: What are the operational cost issues that
need to be examined? Is fee for services a viable approach?
Presenter: Rick Homan, FHI
Moderator: Mike Sweat, Johns Hopkins University

3:00 – 3:20

Break

3:20 – 4:10

Setting Operations Research Priorities for Horizons
Moderator: Johannes van Dam, Horizons

4:10 - 4:20

Wrap-up
Andrew Fisher, Horizons
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Horizons is a global operations research
program designed to:
Identify and test potential strategies to
improve HIV/AIDS prevention, care, and
support programs and service delivery.
Disseminate best practices and utilize
findings with a view toward scaling up
successful interventions.

For more information, please contact:
Horizons Program, Communications Unit
4301 Connecticut Avenue, NW Suite 280
Washington, DC 20008 USA
Tel: 202-237-9400
Fax: 202-237-8410
Email: horizons@pcdc.org
www.popcouncil.org/horizons/horizons.html
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Horizons is implemented by the
Population Council in collaboration with
· International Center for Research on
Women (ICRW)
· International HIV/AIDS Alliance
· Program for Appropriate Technology in
Health (PATH)
· Tulane University
· University of Alabama at Birmingham
· Family Health International (FHI)
· Johns Hopkins University

